{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-000938","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.159006+00:00","generated_at":"2026-06-07T01:25:27.047750+00:00","sec_items":["5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AcelRx rebrands to Talphera; ticker changes to TLPH Jan 10; Niyad PMA submission H2 2024","bullets":["Name changed from AcelRx Pharmaceuticals to Talphera, Inc.; new symbol TLPH effective Jan 10.","Rebranding reflects broader focus on medically supervised settings; lead candidate Niyad for dialysis circuit.","Niyad's registrational NEPHRO study to begin shortly; first patient expected Q1 2024.","PMA submission for Niyad targeted for H2 2024; product has FDA Breakthrough Designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-000938","json":"https://secwatch.observer/filing/0001437749-24-000938.json","markdown":"https://secwatch.observer/filing/0001437749-24-000938.md","text":"https://secwatch.observer/filing/0001437749-24-000938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924000938/0001437749-24-000938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924000938/acrx20240108_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:25:27.047750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"410ff4f7df32641623d3c5be3c78fe4f25b064db","claim":"TALPHERA, INC.: Certificate of Amendment filed to change company name from AcelRx Pharmaceuticals, Inc. to Talphera, Inc (effective 2024-01-09).","evidence_excerpt":"On January 9, 2024, Talphera, Inc., formerly known as AcelRx Pharmaceuticals, Inc. (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), to change the name of the Company from “AcelRx Pharmaceuticals, Inc.” to “Talphera, Inc.” (the “Name Change”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924000938/0001437749-24-000938-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-01-09"}],"fact_type":"governance_change"},{"claim_id":"e6ab94c6211ccdd9276dd793b099e86ce6c12b9c","claim":"TALPHERA, INC.: Amended and Restated Bylaws to reflect the new corporate name (effective 2024-01-09).","evidence_excerpt":"In connection with the Name Change, the Company amended its Amended and Restated Bylaws to reflect the new corporate name.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774924000938/0001437749-24-000938-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-01-09"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}